MX2019005748A - Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. - Google Patents

Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.

Info

Publication number
MX2019005748A
MX2019005748A MX2019005748A MX2019005748A MX2019005748A MX 2019005748 A MX2019005748 A MX 2019005748A MX 2019005748 A MX2019005748 A MX 2019005748A MX 2019005748 A MX2019005748 A MX 2019005748A MX 2019005748 A MX2019005748 A MX 2019005748A
Authority
MX
Mexico
Prior art keywords
kidney function
methods
biomarkers
same
kidney
Prior art date
Application number
MX2019005748A
Other languages
English (en)
Inventor
Perichon Regis
V Brown Meredith
Kennedy Adam
Edmond Cobb Jeffery
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of MX2019005748A publication Critical patent/MX2019005748A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan biomarcadores de la función renal y métodos para usar los biomarcadores para evaluar la función renal, monitorear la función renal, diagnosticar lesiones renales agudas, y diagnosticar enfermedades renales crónicas. También se proporcionan modalidades de entidades de moléculas pequeñas como biomarcadores para enfermedades renales crónicas.
MX2019005748A 2013-05-14 2015-11-10 Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. MX2019005748A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361822965P 2013-05-14 2013-05-14

Publications (1)

Publication Number Publication Date
MX2019005748A true MX2019005748A (es) 2019-08-12

Family

ID=51898805

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015561A MX365061B (es) 2013-05-14 2014-05-13 Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
MX2019005748A MX2019005748A (es) 2013-05-14 2015-11-10 Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015561A MX365061B (es) 2013-05-14 2014-05-13 Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.

Country Status (11)

Country Link
US (2) US10539575B2 (es)
EP (3) EP3410115A1 (es)
JP (1) JP6595984B2 (es)
CN (2) CN105209909B (es)
AU (1) AU2014265669B2 (es)
BR (1) BR112015028253A2 (es)
CA (2) CA2911204C (es)
ES (2) ES2702123T3 (es)
HK (2) HK1218331A1 (es)
MX (2) MX365061B (es)
WO (1) WO2014186311A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209909B (zh) * 2013-05-14 2019-06-07 梅塔博隆股份有限公司 与肾功能相关的生物标记及其使用方法
KR20170102983A (ko) * 2015-01-09 2017-09-12 글로벌 게노믹스 그룹, 엘엘씨 죽상 경화성 관상 동맥 질환을 진단하기 위한 혈액 기반 바이오마커
US20180003721A1 (en) * 2015-01-15 2018-01-04 Joslin Diabetes Center Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
JP6987123B2 (ja) * 2016-07-28 2021-12-22 メタボルン インコーポレーティッド 化合物、試薬およびその使用
DK3552022T3 (da) * 2016-11-25 2021-08-23 Implexion AB Metaboliske lidelser
CA3045022C (en) 2016-12-19 2024-01-16 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of kidney function metabolites
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN107132266A (zh) * 2017-06-21 2017-09-05 佛山科学技术学院 一种基于随机森林的水质分类方法及系统
CA3072427C (en) 2017-08-08 2023-12-05 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
AU2018341599A1 (en) * 2017-09-28 2020-04-09 Metabolon, Inc. Compounds, reagents, and uses thereof
CN111936859A (zh) * 2018-01-19 2020-11-13 马斯公司 用于猫中慢性肾脏病的生物标志物和分类算法
KR20210127945A (ko) * 2019-02-20 2021-10-25 가부시키가이샤 파트너 펌 고상 반응 칩 및 이것을 사용한 측정 방법
CN112305089B (zh) * 2019-07-26 2022-04-29 长沙都正生物科技股份有限公司 一种慢性肾病诊断生物标记物及其应用
KR20220041883A (ko) * 2019-07-26 2022-04-01 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨) 에르고티오네인, s-메틸-에르고티오네인 및 이들의 용도
CN111487338B (zh) * 2020-04-16 2022-06-10 中南大学湘雅二医院 一种与肾功能相关的无创生物标记物及其应用
CN114026427B (zh) * 2020-05-19 2023-11-17 深圳市中医院 诊断肾病的标志物以及诊断方法
CN114910587B (zh) * 2022-05-12 2024-03-19 军科正源(上海)生物医药科技有限公司 一种尿液检测用高效液相-串联质谱分析方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196787A (ja) * 1989-01-25 1990-08-03 Otsuka Pharmaceut Co Ltd シュードウリジン誘導体
JPH0661278B2 (ja) * 1990-09-18 1994-08-17 旭化成工業株式会社 ミオイノシトールの高感度定量法および定量用組成物
US5712084A (en) * 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
CN101377492B (zh) 2007-08-29 2014-04-23 北京九强生物技术股份有限公司 胱抑素c测定试剂盒
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
US20100273207A1 (en) * 2009-04-24 2010-10-28 Raymond Langley Methods for Diagnosis of Sepsis and Risk of Death
WO2010126146A1 (ja) * 2009-04-30 2010-11-04 Tanaka Noriaki 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
US8637482B2 (en) * 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
WO2011027573A1 (ja) * 2009-09-04 2011-03-10 国立大学法人東北大学 ヒトにおける新たな腎疾患マーカー物質
CA2784889C (en) * 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8980548B2 (en) 2010-05-19 2015-03-17 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
JP5916058B2 (ja) * 2011-08-26 2016-05-11 国立大学法人東北大学 細胞ストレス状態のバイオマーカー
EP2756304A4 (en) * 2011-09-14 2015-06-10 Basf Se MEANS AND METHODS FOR ASSESSING KIDNEY TOXICITY
WO2013048344A1 (en) * 2011-09-29 2013-04-04 National University Of Singapore Urinary metabolomic markers for renal insufficiency
CN105209909B (zh) * 2013-05-14 2019-06-07 梅塔博隆股份有限公司 与肾功能相关的生物标记及其使用方法
JP6987123B2 (ja) * 2016-07-28 2021-12-22 メタボルン インコーポレーティッド 化合物、試薬およびその使用

Also Published As

Publication number Publication date
ES2871823T3 (es) 2021-11-02
EP3546940A1 (en) 2019-10-02
CA2911204C (en) 2023-03-28
EP3410115A1 (en) 2018-12-05
US20160116486A1 (en) 2016-04-28
CN110196335A (zh) 2019-09-03
CA2911204A1 (en) 2014-11-20
CN105209909A (zh) 2015-12-30
JP2016520192A (ja) 2016-07-11
HK1218331A1 (zh) 2017-02-10
CN105209909B (zh) 2019-06-07
ES2702123T3 (es) 2019-02-27
MX365061B (es) 2019-05-22
EP2997366A1 (en) 2016-03-23
HK1222905A1 (zh) 2017-07-14
US10539575B2 (en) 2020-01-21
EP3546940B1 (en) 2021-02-17
AU2014265669B2 (en) 2020-05-14
US20200103417A1 (en) 2020-04-02
MX2015015561A (es) 2016-02-05
EP2997366B1 (en) 2018-10-10
JP6595984B2 (ja) 2019-10-23
BR112015028253A2 (pt) 2017-07-25
AU2014265669A1 (en) 2015-12-24
CA3184836A1 (en) 2014-11-20
EP2997366A4 (en) 2017-04-12
WO2014186311A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
MX2019005748A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
EA201590027A1 (ru) Способы детекции заболеваний или состояний
DK2972351T3 (da) Forbedrede analysemetoder
DK3127563T3 (da) Pumpe, især blodpumpe
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
TR201907981T4 (tr) Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı.
FR3004506B1 (fr) Connexion fluidique securisee.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
DK3041576T3 (da) Fremgangsmåder til at detektere nyresygdom
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
CL2015002358A1 (es) Compuestos bicíclicos.
GB201317621D0 (en) Kidney disease biomarker
EP2966449A4 (en) TOGETHER TO DIAGNOSE RENAL DISEASES
MX363679B (es) Metodo para diagnosticar cancer.
WO2014146111A3 (en) Analgesic compounds and methods of use
ITMI20131876A1 (it) Metodi analitici per la determinazione di polisaccaridi
FI20155596A (fi) Tuotevaihteluiden vähentäminen varianssinositusanalyysin avulla
WO2014172288A3 (en) Digital analyte analysis
UY4289Q (es) Diseño automovil
MX2013010938A (es) Arreglo multiple de anticuerpos especificos para el pronostico, deteccion y vigilancia del proceso fibrogenico.
AU2015901190A0 (en) Computer implemented technologies configured to enable demographic profiling based on resource consumption analysis
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
BR302013004436S1 (pt) Configuração aplicada em bancada.